(
For further information see the attached, plus please visit https://asarinapharma.com/investors/financial-reports/
For further information, please contact:
Peter Nordkild,
CEO,
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
Otto Skolling,
Tel: +46 76 803 0181
E-post: otto.skolling@asarinapharma.com
Jakob Dynnes Hansen,
CFO,
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Certified Adviser
Phone: +46 8-463 83 00
Mail: certifiedadviser@penser.se
About
We are a Swedish biotech company developing Sepranolone, the world's first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years' research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading
This information is information that
https://news.cision.com/asarina-pharma/r/asarina-pharma-annual-report-for-2019-released,c3085343
https://mb.cision.com/Main/17069/3085343/1227685.pdf
https://mb.cision.com/Public/17069/3085343/8b1ef20b8e4a3d77.pdf
(c) 2020 Cision. All rights reserved., source